🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor. NCT07754409n/a1 site📍 Gothenburg Göteborg University Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer NCT06205927Phase 21 site📍 Shanghai Jian Chen · Tests: Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites📍 Washington D.C.📍 Athens📍 Lexington Bristol-Myers Squibb · Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance NCT05692635Phase 21 site📍 Winston-Salem Wake Forest University Health Sciences · Tests: MRI of the Brain, Blood draws, Quality of Life Questionnaires, Gadolinium Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer NCT06865339Phase 21 site📍 The Bronx Montefiore Medical Center · Tests: Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC) Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients NCT06311981Phase 21 site📍 Shanghai Jian Chen · Tests: carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724n/a2 sites📍 Sankt Pölten📍 Frankfurt am Main Institut für Klinische Krebsforschung IKF GmbH at Krankenha… A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer NCT07288632n/a1 site📍 Perugia University Of Perugia FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations NCT06669117Phase 1, Phase 219 sites📍 Washington D.C.📍 Canton📍 Nashville Pierre Fabre Medicament · Tests: VERT-002 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC NCT07863999Phase 35 sites📍 Shanghai📍 Shanghai📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: PD-L1/VEGF Bispecific Antibody, PD-1 Monoclonal Antibody, Nab-paclitaxel, Carboplatin, Surgery A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites📍 Beijing📍 Beijing📍 Guangzhou Henan Genuine Biotech Co., Ltd. · Tests: Dositinib mesylate tablets Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost NCT06627738Phase 21 site📍 Nice Centre Antoine Lacassagne · Tests: Cyberknife irradiation A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3301 sites📍 Mobile📍 Chandler📍 Phoenix AstraZeneca · Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites📍 Springdale📍 Duarte📍 Irvine AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites📍 Tucson📍 Hot Springs📍 Little Rock AstraZeneca · Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790Phase 3204 sites📍 Beverly Hills📍 Fullerton📍 La Jolla Bristol-Myers Squibb · Tests: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation NCT05010109NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress T… Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728Phase 32 sites📍 Changsha📍 Shanghai TYK Medicines, Inc · Tests: TY-9591, placebo Osimertinib, Osimertinib, placebo TY-9591 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer NCT06775678Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy, Conventional fractionated radiotherapy Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT07086456Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Surufatinib, Tislelizumab, Concurrent Chemotherapy, Radiotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy